Beta Bionics, Inc. Common Stock (BBNX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Beta Bionics, Inc. Common Stock stock (BBNX) is currently trading at $11.31. Beta Bionics, Inc. Common Stock PS ratio (Price-to-Sales) is 5.01. Analyst consensus price target for BBNX is $23.42. WallStSmart rates BBNX as Sell.
- BBNX PE ratio analysis and historical PE chart
- BBNX PS ratio (Price-to-Sales) history and trend
- BBNX intrinsic value — DCF, Graham Number, EPV models
- BBNX stock price prediction 2025 2026 2027 2028 2029 2030
- BBNX fair value vs current price
- BBNX insider transactions and insider buying
- Is BBNX undervalued or overvalued?
- Beta Bionics, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- BBNX Piotroski F-Score and Altman Z-Score
- BBNX analyst price target and Smart Rating
Beta Bionics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Beta Bionics, Inc. Common Stock (BBNX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Beta Bionics, Inc. Common Stock (BBNX) Key Strengths (3)
Revenue surging 57.10% year-over-year
109.70% of shares held by major funds and institutions
Trading at 1.74x book value, attractively priced
Supporting Valuation Data
Beta Bionics, Inc. Common Stock (BBNX) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium valuation at 5.0x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Beta Bionics, Inc. Common Stock (BBNX) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Price/Book. Valuation metrics including Price/Book (1.74) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 57.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (5.01) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -40.30%, Operating Margin at -50.20%, Profit Margin at -73.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -40.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 57.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BBNX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BBNX's Price-to-Sales ratio of 5.01x trades 47% below its historical average of 9.37x (25th percentile). The current valuation is 77% below its historical high of 21.35x set in Nov 2025, and 9% above its historical low of 4.6x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~8.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Beta Bionics, Inc. Common Stock (BBNX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Beta Bionics, Inc. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 100M with 57% growth year-over-year. The company is currently unprofitable, posting a -73.0% profit margin.
Key Findings
Revenue growing at 57% YoY, reaching 100M. This pace significantly outperforms most MEDICAL DEVICES peers.
Debt-to-equity ratio of 0.04 indicates a conservative balance sheet with 32M in cash.
The company is unprofitable with a -73.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Beta Bionics, Inc. Common Stock maintain 57%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Beta Bionics, Inc. Common Stock.
Bottom Line
Beta Bionics, Inc. Common Stock is a high-conviction growth story with revenue accelerating at 57% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -73.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Beta Bionics, Inc. Common Stock(BBNX)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.